Home > Cardiology > ACC/WCC 2020 > Genetics and Prevention > Homozygous FH responds to alirocumab

Homozygous FH responds to alirocumab

Presented By
Prof. D. Blom, University of Cape Town, South Africa
Conference
ACC 2020
Trial
ODYSSEY HoFH
In the ODYSSEY HoFH study, alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) in the largest randomised, placebo-controlled clinical trial looking at lipid-lowering in adults with homozygous familial hypercholesterolaemia (HoFH) to date. The primary objective of the study, presented by Prof. Dirk Blom (University of Cape Town, South Africa), was to demonstrate the reduction of LDL-C after subcutaneous alirocumab every 2 weeks compared with placebo after 12 weeks of treatment [1]. The double-blinded trial included 69 adults with genetically confirmed HoFH randomised 2:1 to the PCSK9 inhibitor alirocumab dosed at 150 mg every 2 weeks or placebo while on concurrent intensive background lipid lowering with statins and/or other agents including ezetimibe. Patients’ LDL-C level...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on